Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia

Prognostic factors associated with chemotherapy outcomes in patients with acute myeloid leukemia (AML) are extensively reported, and one gene whose mutation is recognized as conferring resistance to several newer targeted therapies is protein tyrosine phosphatase non-receptor type 11 (PTPN11). The b...

Descripción completa

Detalles Bibliográficos
Autores principales: Fobare, Sydney, Kohlschmidt, Jessica, Ozer, Hatice Gulcin, Mrózek, Krzysztof, Nicolet, Deedra, Mims, Alice S., Garzon, Ramiro, Blachly, James S., Orwick, Shelley, Carroll, Andrew J., Stone, Richard M., Wang, Eunice S., Kolitz, Jonathan E., Powell, Bayard L., Oakes, Christopher C., Eisfeld, Ann-Kathrin, Hertlein, Erin, Byrd, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905707/
https://www.ncbi.nlm.nih.gov/pubmed/34847232
http://dx.doi.org/10.1182/bloodadvances.2021006242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905707/
https://www.ncbi.nlm.nih.gov/pubmed/34847232
http://dx.doi.org/10.1182/bloodadvances.2021006242

Ejemplares similares